Q32 Bio (QTTB) Retained Earnings (2017 - 2026)
Q32 Bio's quarterly Retained Earnings came in at -$212.6 million in Q1 2026, up 13.51% year-on-year from -$187.3 million in Q1 2025, and down 3.71% quarter-over-quarter from -$205.0 million in Q4 2025.
Q32 Bio has reported Retained Earnings for 10 years, with the latest figure at -$212.6 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 13.51% year-over-year to -$212.6 million; the trailing twelve-month figure through Mar 2026 stood at -$212.6 million (up 13.51% YoY), and the FY2025 full-year result was -$205.0 million, up 12.7% from the prior year.
- Retained Earnings for Q1 2026 stood at -$212.6 million, down from -$205.0 million in the prior quarter.
- The five-year high for Retained Earnings was -$5000.0 in Q1 2024, with the low at -$493.0 million in Q2 2023.
- Average Retained Earnings over 5 years is -$241.1 million, with a median of -$234.8 million recorded in 2024.
- Year-over-year, Retained Earnings tumbled 18055900.0% in 2022 and soared 100.0% in 2024.
- Tracing QTTB's Retained Earnings over 5 years: stood at -$404000.0 in 2022, then jumped by 91.09% to -$36000.0 in 2023, then plunged by 652161.11% to -$234.8 million in 2024, then increased by 12.7% to -$205.0 million in 2025, then declined by 3.71% to -$212.6 million in 2026.
- The last three Retained Earnings figures came in at -$212.6 million (Q1 2026), -$205.0 million (Q4 2025), and -$255.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | -212.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212.60 Mn |
| Dec 31, 2025 | -204.99 Mn |
| Jun 30, 2025 | -255.30 Mn |
| Mar 31, 2025 | -245.80 Mn |
| Dec 31, 2024 | -234.81 Mn |
| Sep 30, 2024 | -220.63 Mn |
| Jun 30, 2024 | -203.00 Mn |
| Mar 31, 2024 | -5,000.00 |
| Sep 30, 2023 | -36,000.00 |
| Jun 30, 2023 | -493.00 Mn |
| Mar 31, 2023 | -458.00 Mn |
| Dec 31, 2022 | -404,000.00 |
| Sep 30, 2022 | -394.80 Mn |
| Jun 30, 2022 | -361.12 Mn |
| Mar 31, 2022 | -332.03 Mn |
| Dec 31, 2021 | -424.13 Mn |
| Sep 30, 2021 | -390.50 Mn |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | -329.40 Mn |
| Sep 30, 2020 | -298.58 Mn |
| Jun 30, 2020 | -270.35 Mn |
| Mar 31, 2020 | -235.01 Mn |
| Dec 31, 2019 | -199.67 Mn |
| Sep 30, 2019 | 254,000.00 |
| Jun 30, 2019 | 186,000.00 |
| Mar 31, 2019 | -119.61 Mn |
| Dec 31, 2018 | -77,000.00 |
| Sep 30, 2018 | -78.39 Mn |
| Jun 30, 2018 | -48,646.00 |
| Mar 31, 2018 | -50.70 Mn |
| Dec 31, 2017 | -73,000.00 |